Clinical trials: Cardiac Rhythm Disorder
Atrial Fibrillation, Atrial Flutter
DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial Fibrillation
Atrial fibrillation (AF) is the most common clinical arrhythmia and the prevalence increases with age. AF increases the risk of ischaemic stroke fivefold and accounts for almost one-third of all strokes.
- Trial name
- CONSIDERING-AF (NCT05838781)
- Testing
- Risk prediction model, 14-days continuous ECG monitoring
- Where
- 2 sites in Sweden
- Volunteers
- 2,112 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation, Atrial Inflammation
Inflammation, Fibrosis and Risk of Recurrence After Atrial Fibrillation Ablation
FIBRO-RISK study aims to investigate the impact of inflammatory-mediated myocardial fibrosis on the risk of recurrence after successful ablation of atrial fibrillation.
- Trial name
- FIBRO-RISK (NCT03757741)
- Testing
- Cardiac imaging tests, Venous blood samle collection
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
Atrial Fibrillation, Atrial Flutter
Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation
The purpose of this research study is to test an experimental drug ATI-5923 vs Coumadin. The study is intended to demonstrate ATI-5923 is superior to Coumadin for keeping INR values in the desired therapeutic range.
- Conditions
- Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction
- Trial name
- EmbraceAC (NCT00691470)
- Testing
- ATI-5923, Coumadin (warfarin)
- Where
- 41 sites in United States
- Volunteers
- 600 people
- Sponsor
- ARYx Therapeutics
Atrial Fibrillation, Atrial Flutter
Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
The primary purpose of this study is to optimize drug exposure in the target population.
- Trial name
- NCT01229254
- Testing
- Amiodarone, Betrixaban 60 mg, Betrixaban 90 mg
- Volunteers
- 189 people
- Sponsor
- Portola Pharmaceuticals
Congestive Heart Failure
Monitoring of Arrhythmias and HRV in Patients With Heart Failure Treated With the CRT Pacemaker Renewal TR2
The objective of this study is to evaluate the prevalence of sustained ventricular and supraventricular rhythm disorders in patients implanted with a CONTAK RENEWAL TR2 ventricular resynchronization therapy (CRT) device
- Trial name
- NCT00180531
- Testing
- Renewal TR2
- Where
- 10 sites in France
- Volunteers
- 500 people
- Sponsor
- Guidant Corporation
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults
This study assesses for change in heart rhythm of healthy volunteers taking GSK189075 for 3 days at a normal dose and a higher than normal dose compared to placebo or to a single dose of moxifloxacin.
- Trial name
- NCT00532610
- Testing
- GSK189075
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ventricular Tachycardia, Ventricular Fibrillation
DF4 Master Study (Safety and Efficacy Study)
The purpose of the study is to proof the safety and efficacy of the new ICD sytem (Iforia/Ilesto). The devices are available with DF-1 and DF4 connection. A special focus is set on the ICD system with DF4 connection.
- Conditions
- Ventricular Tachycardia, Ventricular Fibrillation, Sudden Cardiac Death, Heart Failure
- Trial name
- NCT01790841
- Testing
- Iforia/Ilesto ICD/CRT-D, Linox smart DF4 lead/ Protego
- Where
- Germany
- Volunteers
- 240 people
- Sponsor
- Biotronik SE & Co. KG
Atrial Fibrillation
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
The objective is to evaluate whether once weekly subcutaneous (SC) injection of idrabiotaparinux sodium (biotinylated idraparinux) is at least as efficient to prevent clots in brain and in the other organs than oral international…
- Trial name
- BOREALIS-AF (NCT00580216)
- Testing
- Idrabiotaparinux sodium, Warfarin, Avidin
- Where
- 538 sites in United States, Argentina and 46 more
- Volunteers
- 3,773 people
- Sponsor
- Sanofi
Atrial Fibrillation
Efficacy and Safety Study of F373280
The purpose of this study is to assess the efficacy of F373280 on the maintenance of normal cardiac rhythm after direct electric cardioversion in patients with persistent atrial fibrillation and cardiac failure.
- Trial name
- NCT01831856
- Testing
- 1g of F373280
- Where
- 20 sites in Czechia, Hungary and 3 more
- Volunteers
- 135 people
- Sponsor
- Pierre Fabre Medicament
Atrial Fibrillation
Topera E-FIRM Registry
This is a registry to assess the safety and effectiveness of FIRM guided procedures for the treatment of symptomatic any type of atrial fibrillation.
- Trial name
- NCT02386345
- Where
- 9 sites in Germany, Netherlands
- Volunteers
- 299 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
CONcomitant eValuation of Epicor Left atRial Therapy for AF
The purpose of this study is to test the safety and efficacy of the Epicor LP Cardiac Ablation System for treating permanent atrial fibrillation during concomitant open chest and/or open heart surgery for one of more of the…
- Trial name
- CONVERT-AF (NCT00519194)
- Testing
- Epicor LP Cardiac Ablation System, Surgical ablation of permanent AF
- Where
- 15 sites in United States
- Volunteers
- 112 people
- Sponsor
- Abbott Medical Devices
Tachyarrhythmia
Full Automaticity and Remote Follow-up
With the expansion of Sudden Cardiac Death (SCD) primary prevention indications, the number of Implantable Cardioverter Defibrillators (ICD) implants has increased significantly in the recent years.
- Trial name
- NCT01526629
- Where
- France
- Volunteers
- 354 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Prevention of Thromboembolic Events, Atrial Fibrillation
An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting
This is an observational study in which data from people with atrial fibrillation who received or are currently receiving the drug apixaban to prevent thromboembolic events (blood clots that travel through the blood stream to…
- Trial name
- NCT05471830
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Bayer
Atrial Fibrillation (AF), Paroxysmal AF
Dose Escalation Study to Assess Safety, Tolerability, and Efficacy of Budiodarone Treatment With Non-permanent Atrial Fibrillation
This multicenter, open-label study aims to assess the safety, tolerability and efficacy of budiodarone in treating participants with non-permanent AF, in particular paroxysmal atrial fibrillation (PAF).
- Trial name
- Harbor-AF (NCT07792239)
- Testing
- Budiodarone 200 mg BID, Budiodarone 400 mg BID, Budiodarone 600 mg BID
- Where
- 4 sites in Poland
- Volunteers
- 100 people
- Sponsor
- Xyra, LLC
CPVT1, Heart Defects, Congenital
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 when…
- Conditions
- CPVT1, Heart Defects, Congenital, Heart Diseases, Ventricular Tachycardia
- Trial name
- CPVT (NCT06005428)
- Testing
- CRD-4730
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 7 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Paroxysmal Atrial Fibrillation
TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Post Approval Study
A prospective, multicenter, interventional study to collect confirmatory evidence on the safety and effectiveness of the TactiCath® percutaneous ablation catheter in the post approval setting for the treatment of symptomatic…
- Trial name
- TactiCathPAS (NCT02310100)
- Testing
- TactiCath Quartz treatment
- Where
- 20 sites in United States
- Volunteers
- 178 people
- Sponsor
- Abbott Medical Devices
Ventricular Tachycardia
Catheter Evaluation for Endocardial Ablation in Patients With Ventricular Tachycardia
The primary objective is to provide additional corroborative safety and efficacy data for the Navistar ThermoCool catheter for the treatment of subjects with ischemic Ventricular Tachycardia.
- Trial name
- VT-CoA (NCT00412607)
- Testing
- NAVISTAR® THERMOCOOL® Catheter
- Volunteers
- 249 people
- Sponsor
- Biosense Webster, Inc.
Persistent Atrial Fibrillation
Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion
Dose-ranging Phase II study testing the efficacy and safety of 3 doses of Ranolazine (low, intermediate and high, given BID) versus placebo in maintaining sinus rhythm after successful electrical cardioversion in patients with…
- Trial name
- RAFFAELLO (NCT01534962)
- Testing
- Ranolazine
- Where
- 4 sites in Germany, Italy and 2 more
- Volunteers
- 241 people
- Sponsor
- Menarini Group
Atrial Fibrillation
Safety and Performance Study to Evaluate Access to Pulmonary Veins for Treatment of Paroxysmal AF
The study is intended to assess the safety and performance of the Vado™ Steerable Sheath in facilitating ease of access to the pulmonary veins (PV) for the treatment of paroxysmal atrial fibrillation and persistent atrial…
- Trial name
- NCT02521896
- Testing
- Steerable Sheath System
- Volunteers
- 8 people
- Sponsor
- Kalila Medical
Tachycardia, Ventricular
Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)
RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter ablation (CA), for patients with high-risk refractory…
- Trial name
- RADIATE-VT (NCT05765175)
- Testing
- Varian Cardiac Radioablation (CRA), Catheter Ablation (CA)
- Where
- 12 sites in United States
- Volunteers
- 380 people
- Sponsor
- Varian, a Siemens Healthineers Company